SageView Advisory Group LLC Takes $289,000 Position in Hologic, Inc. (NASDAQ:HOLX)

SageView Advisory Group LLC bought a new position in shares of Hologic, Inc. (NASDAQ:HOLX) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 3,861 shares of the medical equipment provider’s stock, valued at approximately $289,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of HOLX. Goldman Sachs Group Inc. raised its position in Hologic by 5.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,314,278 shares of the medical equipment provider’s stock valued at $93,905,000 after purchasing an additional 71,222 shares in the last quarter. Integrated Advisors Network LLC raised its holdings in Hologic by 5.9% in the fourth quarter. Integrated Advisors Network LLC now owns 4,044 shares of the medical equipment provider’s stock valued at $289,000 after acquiring an additional 225 shares in the last quarter. V Square Quantitative Management LLC lifted its stake in Hologic by 23.0% in the fourth quarter. V Square Quantitative Management LLC now owns 5,708 shares of the medical equipment provider’s stock worth $408,000 after acquiring an additional 1,069 shares during the last quarter. Gotham Asset Management LLC grew its holdings in Hologic by 53.8% during the 4th quarter. Gotham Asset Management LLC now owns 222,128 shares of the medical equipment provider’s stock worth $15,871,000 after acquiring an additional 77,663 shares in the last quarter. Finally, Bayesian Capital Management LP purchased a new stake in shares of Hologic in the 4th quarter valued at approximately $4,790,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Performance

NASDAQ HOLX opened at $72.21 on Friday. The firm has a market cap of $16.85 billion, a P/E ratio of 36.84, a P/E/G ratio of 2.38 and a beta of 1.00. Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $82.45. The business’s 50-day moving average price is $74.67 and its 200 day moving average price is $74.11. The company has a quick ratio of 3.29, a current ratio of 3.97 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the business posted $1.06 EPS. The company’s revenue was down .8% on a year-over-year basis. On average, equities research analysts expect that Hologic, Inc. will post 4.08 earnings per share for the current year.

Analyst Ratings Changes

HOLX has been the subject of a number of analyst reports. Argus boosted their target price on shares of Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. Evercore ISI increased their price objective on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and increased their price target for the company from $80.00 to $95.00 in a research note on Wednesday, April 3rd. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Hologic from $85.00 to $91.00 and gave the stock an “overweight” rating in a research report on Friday, May 3rd. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $85.60.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.